patients and looked at people prescribed either semaglutide or liraglutide, two main GLP-1 agonists, between 2006 and 2020
Here are a few questions to help guide your discussions: Is your organization prepared to address obesity as a workforce health priority beyond just GLP-1 access
Doing glp-1 alone isn't dangerous but it's the version that tends to produce disappointing long-term outcomes, because the medication does its job and everything around it is left to chance
Luckily, one expert from Baylor College of Medicine has tips on how to enjoy holiday fare while on these medications, without overdoing it
Our weight loss program in San Francisco, California does prescribe weight loss medications to patients who we feel can benefit from them
( PMID: 8642087 ) DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P (2011) Encapsulation of exenatide in poly-(d, l-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes